{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:02:49Z","timestamp":1790863369646,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009895","name":"Southern Medical Association","doi-asserted-by":"publisher","award":["2022YX-Q0 3"],"award-info":[{"award-number":["2022YX-Q0 3"]}],"id":[{"id":"10.13039\/100009895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009895","name":"Southern Medical Association","doi-asserted-by":"publisher","award":["GSWS2020009"],"award-info":[{"award-number":["GSWS2020009"]}],"id":[{"id":"10.13039\/100009895","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalradiologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Radiology"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.crad.2023.05.022","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T12:00:56Z","timestamp":1687262456000},"page":"e707-e717","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["CT radiomics can predict disease progression within 6 months after chimeric antigen receptor-modified T-cell therapy in relapsed\/refractory B-cell non-Hodgkin's lymphoma patients"],"prefix":"10.1016","volume":"78","author":[{"given":"R.","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.crad.2023.05.022_bib1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.beha.2018.04.001","article-title":"CAR T cell therapy for B-cell lymphomas","volume":"31","author":"Chavez","year":"2018","journal-title":"Best Pr Res Clin Haematol"},{"issue":"11","key":"10.1016\/j.crad.2023.05.022_bib2","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.6004\/jnccn.2017.7045","article-title":"Emerging role of CAR T cells in non-Hodgkin\u2019s lymphoma","volume":"15","author":"Avanzi","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"issue":"26","key":"10.1016\/j.crad.2023.05.022_bib3","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1182\/blood.2021014497","article-title":"Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL","volume":"139","author":"Gauthier","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.crad.2023.05.022_bib4","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1158\/2326-6066.CIR-20-0675","article-title":"CD19\/CD22 dual-targeted CAR T-cell therapy for relapsed\/refractory aggressive B-cell lymphoma: a safety and efficacy study","volume":"9","author":"Wei","year":"2021","journal-title":"Cancer Immunol Res"},{"issue":"6","key":"10.1016\/j.crad.2023.05.022_bib5","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1016\/j.crad.2023.05.022_bib6","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.crad.2023.05.022_bib7","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.crad.2023.05.022_bib8","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.crad.2023.05.022_bib9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"Suppl. 1","key":"10.1016\/j.crad.2023.05.022_bib10","first-page":"S12","article-title":"CD19\/CD22 dual-targeted CAR-T therapy active in relapsed\/refractory DLBCL","volume":"25","author":"Anon","year":"2020","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.crad.2023.05.022_bib11","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.3109\/10428194.2015.1094694","article-title":"Current imaging follow-up of non-Hodgkin lymphoma exposes patients to significant radiation but does not detect asymptomatic relapses","volume":"57","author":"Riva","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.crad.2023.05.022_bib12","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/RLU.0000000000004060","article-title":"Lesion-based radiomics signature in pretherapy 18F-FDG PET predicts treatment response to ibrutinib in lymphoma","volume":"47","author":"Jimenez","year":"2022","journal-title":"Clin Nucl Med"},{"issue":"7467","key":"10.1016\/j.crad.2023.05.022_bib13","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature12625","article-title":"The causes and consequences of genetic heterogeneity in cancer evolution","volume":"501","author":"Burrell","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.crad.2023.05.022_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1148\/radiol.2021200928","article-title":"A CT-based radiomics signature is associated with response to immune checkpoint inhibitors in advanced solid tumors","volume":"299","author":"Ligero","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.crad.2023.05.022_bib15","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1007\/s00259-021-05572-0","article-title":"A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [(18)F]FDG PET\/CT","volume":"49","author":"Zhang","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1016\/j.crad.2023.05.022_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101188","article-title":"CT-based radiomics model with machine learning for predicting primary treatment failure in diffuse large B-cell lymphoma","volume":"14","author":"Santiago","year":"2021","journal-title":"Transl Oncol"},{"issue":"13","key":"10.1016\/j.crad.2023.05.022_bib17","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1007\/s00259-022-05916-4","article-title":"Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET\/CT radiomics features","volume":"49","author":"Eertink","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.crad.2023.05.022_bib18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2967\/jnumed.121.262117","article-title":"Quantitative radiomics features in diffuse large B-cell lymphoma: does segmentation method matter?","volume":"63","author":"Eertink","year":"2021","journal-title":"J Nucl Med"},{"issue":"27","key":"10.1016\/j.crad.2023.05.022_bib19","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.crad.2023.05.022_bib20","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.crad.2023.05.022_bib21","first-page":"747","article-title":"Dual-layer spectral detector CT in comparison with FDG-PET\/CT for the assessment of lymphoma activity","volume":"197","author":"Gehling","year":"2022","journal-title":"Rofo"},{"issue":"8","key":"10.1016\/j.crad.2023.05.022_bib22","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1007\/s00330-020-06768-y","article-title":"Classification of pulmonary lesion based on multiparametric MRI: utility of radiomics and comparison of machine learning methods","volume":"30","author":"Wang","year":"2020","journal-title":"Eur Radiol"},{"issue":"2","key":"10.1016\/j.crad.2023.05.022_bib23","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00330-021-08250-9","article-title":"Gd-EOB-DTPA-enhanced MRI radiomics to predict vessels encapsulating tumor clusters (VETC) and patient prognosis in hepatocellular carcinoma","volume":"32","author":"Yu","year":"2021","journal-title":"Eur Radiol"},{"key":"10.1016\/j.crad.2023.05.022_bib24","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.csbj.2019.07.004","article-title":"Dual-energy CT texture analysis with machine learning for the evaluation and characterization of cervical lymphadenopathy","volume":"17","author":"Seidler","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"issue":"1","key":"10.1016\/j.crad.2023.05.022_bib25","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2463\/mrms.mp.2017-0178","article-title":"Machine learning-based texture analysis of contrast-enhanced MR imaging to differentiate between glioblastoma and primary central nervous system lymphoma","volume":"18","author":"Kunimatsu","year":"2019","journal-title":"Magn Reson Med Sci"},{"issue":"4","key":"10.1016\/j.crad.2023.05.022_bib26","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1080\/10428190601187703","article-title":"The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma\u2014a population-based study","volume":"48","author":"Hasselblom","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.crad.2023.05.022_bib27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/10428194.2012.691482","article-title":"Prognostic role of gender in diffuse large B-cell lymphoma treated with rituximab containing regimens: a Fondazione Italiana Linfomi\/Grupo de Estudos em Mol\u00e9stias Onco-Hematol\u00f3gicas retrospective study","volume":"54","author":"Carella","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.crad.2023.05.022_bib28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2010.33.3369","volume":"30","author":"Cairo","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.crad.2023.05.022_bib29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1034\/j.1600-0609.2000.90117.x","article-title":"Different alterations in lactate dehydrogenase activity and profile of peripheral blood mononuclear cells in Hodgkin\u2019s and non-Hodgkin\u2019s lymphomas","volume":"64","author":"Jurisi\u0107","year":"2000","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1016\/j.crad.2023.05.022_bib30","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.crad.2023.05.022_bib31","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.crad.2023.05.022_bib32","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.crad.2023.05.022_bib33","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1756-9966-28-87","article-title":"Non-Hodgkin lymphoma response evaluation with MRI texture classification","volume":"28","author":"Harrison","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.crad.2023.05.022_bib34","article-title":"Prognostic value of radiomic features of (18)F-FDG PET\/CT in patients with B-cell lymphoma treated with CD19\/CD22 dual-targeted chimeric antigen receptor T cells","volume":"12","author":"Zhou","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.crad.2023.05.022_bib35","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1007\/s00330-020-06815-8","article-title":"Baseline (18)F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy","volume":"30","author":"Aide","year":"2020","journal-title":"Eur Radiol"},{"issue":"3","key":"10.1016\/j.crad.2023.05.022_bib36","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1007\/s00259-021-05480-3","article-title":"(18)F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma","volume":"49","author":"Eertink","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"10.1016\/j.crad.2023.05.022_bib37","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.3390\/jcm11061522","article-title":"Value of CT-textural features and volume-based PET parameters in comparison to serologic markers for response prediction in patients with diffuse large B-cell lymphoma undergoing CD19-CAR-T cell therapy","volume":"11","author":"Reinert","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.crad.2023.05.022_bib38","first-page":"1","article-title":"Prediction of TTF-1 expression in non-small-cell lung cancer using machine learning-based radiomics","author":"Zhang","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"10.1016\/j.crad.2023.05.022_bib39","doi-asserted-by":"crossref","first-page":"6953","DOI":"10.1007\/s00330-022-08830-3","article-title":"CT-based radiomics analysis of different machine learning models for differentiating benign and malignant parotid tumors","volume":"32","author":"Zheng","year":"2022","journal-title":"Eur Radiol"},{"issue":"11","key":"10.1016\/j.crad.2023.05.022_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224365","article-title":"Machine learning algorithm validation with a limited sample size","volume":"14","author":"Vabalas","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.crad.2023.05.022_bib41","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12859-023-05156-9","article-title":"Evaluation of a decided sample size in machine learning applications","volume":"24","author":"Rajput","year":"2023","journal-title":"BMC Bioinform"}],"container-title":["Clinical Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009926023002349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009926023002349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:13:22Z","timestamp":1762114402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009926023002349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0009926023002349"],"URL":"https:\/\/doi.org\/10.1016\/j.crad.2023.05.022","relation":{},"ISSN":["0009-9260"],"issn-type":[{"value":"0009-9260","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CT radiomics can predict disease progression within 6 months after chimeric antigen receptor-modified T-cell therapy in relapsed\/refractory B-cell non-Hodgkin's lymphoma patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crad.2023.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}]}}